DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sandoz - 3 Ludwig Burger - 2 Rachel More - 2 Charles Platiau - 1 Kisqali - 1 Vas - 1 Kesimpta - 1 drugmaker - 1
Top related locs:
Swiss Rueil Malmaison Paris France Basel Stein Switzerland
Top related orgs:
Novartis - 3 Sandoz - 3 Thomson - 3 REUTERS - 2 Companies Novartis - 2 FRANKFURT - 2 SIX Swiss Exchange - 2 Swiss - 1

Search resuls for: "Companies Novartis"


6 mentions found


☆ Novartis lifts sales growth target to 5% per year through 2027
  + stars: | 2023-11-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +1 min
The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo Acquire Licensing RightsCompanies Novartis AG FollowSandoz GmbH FollowFRANKFURT, Nov 28 (Reuters) - Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business. The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday. The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta. Reporting by Ludwig Burger; Editing by Miranda Murray and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.
Persons: Charles Platiau, Kisqali, Vas, Kesimpta, drugmaker, Sandoz, Ludwig Burger, Miranda Murray, Miral Organizations: Swiss, Novartis, REUTERS, Companies Novartis, Sandoz, FRANKFURT, Thomson Locations: Rueil, Malmaison, Paris, France, Basel, Swiss
☆ Novartis confirms Sandoz spin-off for October 4, 2023
  + stars: | 2023-09-25 | by ( ) www.reuters.com   time to read: 1 min
The company's logo is seen at the cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsCompanies Novartis AG FollowZURICH, Sept 25 (Reuters) - Novartis (NOVN.S) on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month. Novartis also said key regulatory approvals have been obtained, including the approval by SIX Exchange Regulation for the listing of the Sandoz shares on the SIX Swiss Exchange. The Sandoz shares will have the symbol SDZ, Novartis said. Reporting by John Revill, Editing by Rachel MoreOur Standards: The Thomson Reuters Trust Principles.
Persons: Arnd, Sandoz, John Revill, Rachel More Organizations: Novartis, REUTERS, Companies Novartis, SIX, Sandoz, SIX Swiss Exchange, Thomson Locations: Swiss, Stein, Switzerland
☆ Novartis raises 2023 forecast, maps out Sandoz spin-off
  + stars: | 2023-07-18 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
Companies Novartis AG FollowSandoz GmbH FollowFRANKFURT, July 18 (Reuters) - Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast on strong drug sales and mapped out the planned spin-off and stock market debut of its generic medicines division Sandoz for early October. The Swiss drugmaker said in a statement it expected group core operating income to grow by a "low double-digit" percentage in 2023, up from high single-digit growth previously projected. Novartis shareholders will vote on the proposed Sandoz spin-off and complete separation at an extraordinary general meeting on Sept. 15. Gains were driven by better-than-expected sales of heart failure drug Entresto, up 37% in local currencies at $1.52 billion. Kesimpta, a new once-a-month injection against multiple sclerosis, also beat expectations with quarterly revenues more than doubling to $489 million.
Persons: Swiss drugmaker, Sandoz, Harry Kirsch ., Kirsch, Ludwig Burger, Rachel More, Sharon Singleton Organizations: Novartis, Sandoz, FRANKFURT, SIX Swiss Exchange, Swiss pharma, Thomson Locations: Swiss, United States, New Jersey
☆ Amgen sues Novartis to block generic osteoporosis, bone cancer drugs
  + stars: | 2023-05-02 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +1 min
REUTERS/Robert GalbraithCompanies Novartis AG FollowAmgen Inc Follow(Reuters) - Amgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents. Amgen asked the court to block Sandoz's biosimilars of the drugs until its patents expire. Thousand Oaks, California-based Amgen sold $3.6 billion worth of Prolia and $2 billion worth of Xgeva last year, according to a company report. The FDA accepted Sandoz's application for biosimilar versions of the Amgen biologic drugs — which are derived from living cells, unlike traditional small-molecule drugs — in February. Amgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.
☆ Novartis names Firmenich CEO as chairman designate of Sandoz
  + stars: | 2023-02-20 | by ( ) www.reuters.com   time to read: 1 min
Companies Novartis AG FollowSandoz GmbH FollowZURICH, Feb 20 (Reuters) - Novartis (NOVN.S) on Monday announced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis wants to spin off later this year. Ghostine has been CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014. He will become the chairman of the new board at Sandoz, which is to be formed after its spin-off from Novartis in the second half of 2023, subject to final Novartis Board of Directors and shareholder approvals. Reporting by John Revill Editing by Paul CarrelOur Standards: The Thomson Reuters Trust Principles.
☆ GSK Taps Burberry Executive As CFO
  + stars: | 2022-09-26 | by ( Jennifer Williams-Alvarez | Mark Maurer | ) www.wsj.com   time to read: +3 min
Pharmaceutical firm GSK PLC hired the finance chief of British luxury fashion group Burberry Group PLC to lead its finances as it works to develop new medicines after the recent spinoff of its consumer-health business. Brentford, U.K.-based GSK, a maker of cancer and asthma medications, on Monday named Julie Brown as chief financial officer and executive director, effective next spring. Ms. Brown serves as chief operating and financial officer at Burberry, a role she has held since 2017. “Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector,” Emma Walmsley, chief executive officer at GSK, said in a release. Burberry on Friday said a search is under way for the successor of Ms. Brown.
0 next >>
Total: 6